Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Brokerages

Key Points

• Thirteen analysts give Monopar Therapeutics a consensus recommendation of Buy (10 buys, 2 strong buys, 1 sell) with an average 12‑month price target of $107, and Morgan Stanley initiating coverage with an Overweight rating and $115 target.
• Shares opened at $56.22 and were trading down about 2.6%, with a 12‑month range of $28.40–$105.00 and a market cap near $376M; the company remains loss‑making (last quarter EPS -$0.61 missed estimates) and analysts forecast -$1.65 EPS for the fiscal year.
• Several hedge funds recently built positions (Wellington, Siren, Deerfield, TCG) and RA Capital increased holdings to 667,207 shares (~$43.6M), while institutional ownership is reported at just 1.83%.

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) have earned a consensus recommendation of "Buy" from the thirteen research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, ten have issued a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $107.00.

Several equities research analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Monopar Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, April 11th. Chardan Capital reissued a "buy" rating and issued a $100.00 target price on shares of Monopar Therapeutics in a research note on Monday, March 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of Monopar Therapeutics in a research note on Thursday, January 22nd. Cantor Fitzgerald reissued an "overweight" rating on shares of Monopar Therapeutics in a research note on Wednesday, January 21st. Finally, Morgan Stanley assumed coverage on shares of Monopar Therapeutics in a research note on Friday, January 9th. They issued an "overweight" rating and a $115.00 target price on the stock.

Monopar Therapeutics Trading Down 2.6%

Shares of MNPR opened at $56.22 on Friday. Monopar Therapeutics has a twelve month low of $28.40 and a twelve month high of $105.00. The company has a market cap of $376.11 million, a P/E ratio of -30.89 and a beta of 1.64. The company's fifty day simple moving average is $56.38 and its 200-day simple moving average is $69.88.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Friday, March 27th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.10). Analysts predict that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MNPR. Wellington Management Group LLP bought a new position in shares of Monopar Therapeutics in the third quarter worth about $18,904,000. Siren L.L.C. bought a new position in shares of Monopar Therapeutics in the fourth quarter worth about $13,863,000. Deerfield Management Company L.P. bought a new position in shares of Monopar Therapeutics in the third quarter worth about $13,048,000. RA Capital Management L.P. grew its holdings in shares of Monopar Therapeutics by 30.5% in the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company's stock worth $43,569,000 after purchasing an additional 156,000 shares during the last quarter. Finally, TCG Crossover Management LLC bought a new position in shares of Monopar Therapeutics in the third quarter worth about $12,496,000. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.